Predictmedix Launches Next Generation Business Website

0

TORONTO, ON / ACCESSWIRE / October 12, 2021 / Predictmedix Inc. (CSE: PMED) (OTCQB: PMEDF) (“Predictmedix” or the “Company”), an emerging provider of rapid health screening solutions powered by proprietary artificial intelligence (AI), announced today the official launch of its next -generation, corporate website redesign www.predictmedix.com, reflecting the continued efforts to provide up-to-date information to potential clients and investors.

The new website has been designed to be more dynamic, user-friendly and content-rich – best showcasing the company’s AI technologies for workplace health and safety and healthcare. It offers a clean, modern design integrated with useful information and personalized landing pages for marketing to customers considering the company’s proprietary Safe Entry Station fast filtering solution. The website also has an up-to-date investor relations section, including press releases, current share price, regulatory documents and more.

“Our new website will provide Predictmedix with an enhanced online marketing presence that will showcase our AI-based products to corporate clients and investors,” said Dr. Rahul Kushwah, COO of Predictmedix. “With a focus on rapid automated COVID-19 screening in offices, manufacturing, warehouses, nursing homes and at major events, the website better illustrates our wide range of solutions for generating new prospects.

“The Investor Relations pages provide our shareholders and potential investors with up-to-date and easily accessible information on our operations, business strategy, stock profile and more, reflecting our continued commitment to improve transparency and communication with shareholders. The Company has made substantial operational achievements in recent months. , including significant progress in securing Level 1 deployments of our secure entry stations with customers around the world, and an updated website will help us continue to raise our profile. “

About Predictmedix Inc.

Predictmedix (CSE: PMED) (OTCQB: PMEDF) is a world leader in rapid screening and remote patient care solutions. The company’s secure entry stations – powered by proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and predict a variety of health issues, including infectious diseases such as COVID-19 , impaired by drugs or alcohol, or various mental illnesses. Predictmedix’s proprietary remote patient care platform provides healthcare professionals with a suite of AI-powered tools to improve patient health outcomes. For more information, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram Where LinkedIn.

Investor Relations Contact
Lucas A. Zimmerman
MZ Group – MZ North America
949-259-4987
[email protected]
www.mzgroup.us

Caution regarding forward-looking information:

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE QUALITY OR ACCURACY OF THIS COMMUNICATION.

This press release may contain forward-looking statements and information based on current expectations. These statements should not be interpreted as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from those implied by such statements. Although these statements are based on reasonable assumptions of management, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The securities of the Company have not been registered under the US Securities Act of 1933, as amended (the “US Securities Act”), or applicable state securities laws, and may not be offered or sold. to, or on behalf of or for the benefit of, persons in the United States or “US Persons”, as such term is defined in regulations under the US Securities Act, in the absence of registration or an applicable exemption of these registration requirements. This press release does not constitute an offer to sell or the solicitation of an offer to buy and there will be no sale of securities in the United States or in any jurisdiction in which such an offer, solicitation or sale would be. illegal. In addition, there are known and unknown risk factors which could cause the actual results, performance or achievements of the Company to differ materially from the future results, performances or achievements expressed or implied by the forward-looking information contained in the this document, such as, but not limited to reliance on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the company’s control, including risks related to COVID-19; risks relating to the Company’s shares, including price volatility due to events which may or may not be under the control of that party; dependence on management; and the urgency of additional competitors in the industry.

All forward-looking information contained in this document is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update such forward-looking information or to publicly announce the result of any revision of either. forward-looking information contained herein to reflect future results, events or developments, except as required by law.

Disclaimer: “The company makes no express or implied representation that its product has the ability to diagnose, eliminate, cure, or contain COVID-19 (or the SARS-2 coronavirus) for the moment. “

THE SOURCE: Predictmedix

See the source version on accesswire.com:
https://www.accesswire.com/666715/Predictmedix-Launches-Next-Generation-Corporate-Website


Source link

Leave A Reply

Your email address will not be published.